Zanolimumab (Anti-Human CD4 Recombinant Antibody) is a fully human monoclonal antibody that targets the CD4 molecule and effectively inhibits T-cell receptor (TCR) signal transduction. It is used in the research of rheumatoid arthritis, psoriasis, melanoma, cutaneous, and peripheral T-cell lymphoma [1].

Zanolimumab（10和100 ng/mL）对CD4+ T细胞具有强烈的杀伤作用，对CD45RO+亚群的效果优于CD45RA+亚群[1]。Zanolimumab（1-10000 ng/mL）以Fc作用和剂量依赖性降低纯化的初级CD4+ T细胞和SUP-T1 T细胞中CD4水平[1]。Zanolimumab（1-10000 ng/mL）强效抑制TCR激活的T细胞增殖，包括破伤风毒素诱导和抗CD3诱导的T细胞增殖[1]。Zanolimumab（0-30分钟）抑制TCR信号转导[1]。